“We are closely monitoring the clinical trials and regulatory approvals and would be ready to launch the drug soon after the required regulatory approvals. We also plan to manufacture the drug’s active pharmaceutical ingredient (API) internally and assist it with cost-effectiveness and consistent availability, ”said Jubilant Life Sciences chairman Shyam Bhartia and CEO Hari S Bhartia in a statement.
ET had reported on May 5 that Gilead Sciences was in talks with several Indian companies, including Jubilant Life Sciences, about a licensing deal.
Jubilant also has the right to receive a technology transfer of Gilead Sciences’ manufacturing process to scale up production to enable rapid access to the drug for Covid-19 patients, following approval from regulators in the respective countries.
Remdesivir is one of the most widely monitored drugs for the treatment of coronavirus. In April, it received an emergency approval from the US Food and Drug Administration (USFDA), making it the first approved therapy for the virus. USFDA approval was based on trial results which showed that the drug reduced the recovery time to five days from 10 days for moderate patients.
Gilead Sciences is in talks with other Indian companies about similar licensing agreements, ET has heard.